Keywords: uk, nice, recommends, first-line, use, novartis, glivec

UK NICE recommends first-line use of Novartis' Glivec in chronic-phase CML

Article | 08 September 2003

Print This

The National Institute for Clinical Excellence has recommended that Novartis' Glivec (imatinib) be used as a first-line treatment for people ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in